First Drug to Initiate for Social Anxiety Disorder
For social anxiety disorder, escitalopram or sertraline should be initiated as first-line pharmacotherapy 1.
Rationale for First-Line SSRI Selection
The 2023 Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guideline explicitly identifies escitalopram and sertraline as first-line drugs for social anxiety disorder 1. This recommendation aligns with international consensus, as the NICE guidelines in the United Kingdom similarly list these two agents as first-line options.
Why These Specific SSRIs?
- Escitalopram and sertraline have the strongest evidence base with 26 randomized controlled trials supporting SSRI use in social anxiety disorder 1
- These agents demonstrate superior tolerability compared to alternatives
- Other SSRIs (fluvoxamine, paroxetine) are relegated to second-line status due to higher rates of side effects or discontinuation symptoms, despite equal efficacy 1
Practical Initiation Strategy
Start with the lowest available dose and escalate gradually:
- Monitor for response over at least 4 weeks at therapeutic dose
- Use small dose increments with at least one week between adjustments
- The effective dose typically matches standard antidepressant dosing for SSRIs
Critical Monitoring Point
In the first weeks after initiating treatment, systematically inquire about suicidal ideation at each contact 2. While SSRIs like fluoxetine are considered safer than tricyclic antidepressants (particularly in overdose), early treatment phases require vigilance for emergence of suicidal thoughts, especially if akathisia develops as a side effect.
Alternative First-Line Option
If the patient refuses or cannot tolerate pharmacotherapy, cognitive behavioral therapy (CBT) based on the Clark and Wells model or Heimberg model should be offered as an alternative first-line treatment 1. Individual CBT sessions (approximately 14 sessions over 4 months, 60-90 minutes each) are prioritized over group therapy due to superior clinical and health-economic effectiveness.
Common Pitfall to Avoid
Do not prescribe benzodiazepines as first-line treatment. While the Canadian CPG lists benzodiazepines (alprazolam, bromazepam, clonazepam) as second-line options, they should only be considered after SSRI failure, not as initial therapy 1.